Briya Expands Access to European Real-World Data Through Strategic Partnership with Casa Sollievo della Sofferenza

By on    Internet  

Briya (http://www.briya.com/), a leading healthcare data retrieval network, is proud to announce a strategic partnership with Casa Sollievo della Sofferenza, one of Italy s premier hospitals renowned for its advanced medical care and research initiatives. This collaboration marks a significant step in addressing a long-standing challenge in European medical research: the difficulty of accessing high-quality, real-world data (RWD) across the region.

Founded by Saint Pio of Pietrelcina and inaugu

TOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region

By on    Internet  

A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions – often completed in under 90 seconds.

TOOsonix A/S, a leader in high-intensity focused ultrasound technology for dermatology, has partnered with MikronMed AB, a top distributor of medical equipment in the Nordic region. The collaboration will bring TOOsonix inn

MIDEUROPA-BACKED DIAGNOSTYKA MAKES ITS WARSAW STOCK EXCHANGE DEBUT

By on    Internet  

MidEuropa, a leading private equity investor with deep roots in Central Europe, announces that its portfolio company, Diagnostyka, a leading provider of medical diagnostic services in Poland, has debuted on the Warsaw Stock Exchange on Friday, February 7, 2025.

The market closing price on the first day of trading puts Diagnostyka s market capitalisation at over €1 billion. Diagnostyka thus ranks as the second-largest publicly listed healthcare services provider in Central Europe and among

CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration

By on    Electronics & Semiconductors, Picture Gallery  

CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration

The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.

m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.

"We are proud to be a partner in the m2M p

Nomination period for the Broermann Medical Innovation Award started

By on    Electronics & Semiconductors, Picture Gallery  

Nomination period for the Broermann Medical Innovation Award started

– Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
– Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields

The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.

The n

BAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked IVF System

By on    Internet  

The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market

BAIBYS™ (https://www.baibys.com/), a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system (https://www.youtube.com/watch?v=Vaa_HlxuAm0). This milestone enables the company to commercialize its autonomous sperm selection technology across Europe, marking a significant

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

By on    Internet, Picture Gallery  

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releases (https://norgine.com/media)

Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

By on    Internet, Picture Gallery  

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

By on    Internet  

Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel s largest HMO. Over the next five years, Pulsenmore will supply 25,000 units of its advanced home ultrasound devices to support Clalit s commitment to accessible, high-quality prenatal care.

Under the new agreement, Pulsenmore s devices will enable pregnant women to conduct ultrasound scans at home, both asyn

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference

By on    Internet  

Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee s Oral Delivery of Biologics Platform at the 14th Annual PODD Conference – Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024.

Presentation Title: "Breakthrough Device for Oral Delivery of Biologics".

Date & Time: October 22, 2024, 2:30 PM – 2:45 PM

Presenter: Dr. Gil Cohen, PhD, VP R&D

Epitomee s presentation will cover t

1 2